Universal hepatitis B vaccination in Belgium: impact on serological markers 3 and 7 years after implementation
Universal hepatitis B vaccination in Belgium: impact on serological markers 3 and 7 years after implementation
复制标题
比利时全民乙型肝炎疫苗接种：实施后 3 年和 7 年对血清学标志物的影响
DOI：
10.1017/s0950268813001064
复制
发表时间：
2013
影响因子：
4.2
通讯作者：
P. Damme
中科院分区：
文献类型：
--
作者：
H. Theeten;V. Hutse;K. Hoppenbrouwers;P. Beutels;P. Damme
摘要 乙型肝炎病毒 (HBV) 可以通过有效的普遍疫苗接种来消除。比利时于 1999 年推出了针对婴儿的免费 HBV 疫苗接种计划，并在青少年中进行追赶。为了评估对 20 岁以下儿童的效果，对实施该计划 7-8 年后收集的 2443 份残留血清的血清保护（根据测定，抗 HBs >11 mIU/ml）和感染标志物（抗 HBc、HBsAg）进行了评估。单纯抗 HBs 血清保护（“接种疫苗”）血清状态的最大患病率在 1 岁时为 82·9%，在 13 岁时为 60·5%。经过四年前进行的类似血清调查后，发现该活动的目标年龄组明显增加。乙型肝炎病毒感染率保持在较低水平（2006年为1·8%），与疫苗接种前的数据（1993-1994年）相似。我们的结论是，尽管存在地区差异，但普遍乙型肝炎疫苗接种已经实现了总体高水平的疫苗诱导免疫力，这可能会在未来产生一些易感的年轻人。
SUMMARY Hepatitis B virus (HBV) can be eliminated by effective universal vaccination. In Belgium, a free-of-charge HBV vaccination programme in infants with catch-up in adolescents was introduced in 1999. To evaluate the effects in <20-year-olds, seroprotection (anti-HBs >11 mIU/ml, according to the assay) and markers of infection (anti-HBc, HBsAg) were assessed in 2443 residual sera collected 7–8 years after implementation of the programme. The maximal prevalence of a solely anti-HBs seroprotective (‘vaccinated’) serostatus was 82·9% at age 1 year and 60·5% at age 13 years. A clear increase was found in age cohorts targeted by the campaign after a similar serosurvey conducted 4 years earlier. The prevalence of HBV infection remained unchanged at a low level (1·8% in 2006) similar to pre-vaccination data (1993–1994). We conclude that universal HBV vaccination has achieved overall high levels of vaccine-induced immunity, despite regional variations, which may give rise to pockets of susceptible young adults in the future.